PharmaLogic Holdings Corp. Acquires Majority Stake in Agilera Pharma AS

Image Credit: Adobe Stock Images/Yingyaipumi

PharmaLogic Holdings Corp., a contract development and manufacturing organization (CDMO), announced that it has agreed to terms with Norway’s Institute for Energy Technology to acquire a majority stake in Agilera Pharma AS. According to the company, the strategic move aims to establish PharmaLogic as the first fully integrated, global CDMO focused exclusively on radiopharmaceutical therapeutics.

Under the terms of the acquisition, Agilera will work to augment PharmaLogic’s existing therapeutic manufacturing platform, expanding its capacity to deliver high-quality radiopharmaceutical solutions. PharmaLogic also intends to invest in expanding Agilera’s CDMO capabilities by upgrading its infrastructure and increasing production capacity to meet growing global demand. Financial terms of the deal were not immediately disclosed.

"PharmaLogic's acquisition of Agilera, one of only two CDMOs worldwide currently manufacturing radiopharmaceutical therapeutics, accelerates the expansion of our capabilities in this high-growth field," said Etienne Montagut, president, PharmaLogic, in a press release. "By combining our expertise with Agilera's industry-leading scale and quality systems, we will be uniquely positioned to offer an end-to-end solution for manufacturing therapeutics at scale and ultimately improve global patient access to these essential treatments. We're thrilled to welcome Agilera's very talented team to PharmaLogic and to take the lead in expanding our presence in Europe."

The transaction is expected to close in June 2025, pending customary regulatory approvals and closing conditions. PharmaLogic was advised by Solomon Partners Securities, LLC, in connection with the acquisition.¹

In October 2024, PharmaLogic opened new radiopharmaceutical production facilities in Los Angeles, Calif. and Salt Lake City, Utah.2,3 Originally acquired in 2022, the Los Angeles site is designed to support collaboration with leading healthcare providers and researchers in developing novel radiopharmaceuticals.²

"At Agilera, we highly welcome PharmaLogic as a majority shareholder in the company,” said Erik Flatmark, CEO, Agilera, in the press release. “Agilera's most important asset is the experience and expertise of our employees, as the company with the longest experience in large-scale production of radiotherapeutics globally. With PharmaLogic as a new owner beside IFE, this will enable further investments in the business to ensure that we have the right, available capacity to take on new customer projects and thus achieve faster adaptation to the promising market opportunities. An important step will be to strengthen European and transatlantic distribution of the products from both companies. We feel confident that we together will provide great opportunities for European, US, and global customers, with increased manufacturing capacity and capability in the market."

References

1. PharmaLogic to Acquire Majority Stake in Agilera, Strengthening Global Expertise in Radiopharmaceutical Therapeutics. PR Newswire. April 9, 2025. Accessed April 9, 2025. https://prnmedia.prnewswire.com/news-releases/pharmalogic-to-acquire-majority-stake-in-agilera-strengthening-global-expertise-in-radiopharmaceutical-therapeutics-302424316.html

2. PharmaLogic announces opening of radiopharmaceutical production facility in Los Angeles. PR Newswire. October 29, 2024. Accessed April 9, 2025. https://prnmedia.prnewswire.com/news-releases/pharmalogic-announces-opening-of-radiopharmaceutical-production-facility-in-los-angeles-302288746.html

3. PharmaLogic announces opening of new state-of-the-art radiopharmaceutical production facility in Salt Lake City. PR Newswire. October 18, 2024. Accessed April 9, 2025. https://prnmedia.prnewswire.com/news-releases/pharmalogic-announces-opening-of-new-state-of-the-art-radiopharmaceutical-production-facility-in-salt-lake-city-302279817.html